Date: 2012-10-10
Type of information: R&D agreement
Compound: investigational tuberculosis vaccine
Company: Aeras (USA), GSK (UK)
Therapeutic area: Infectious diseases
Type agreement: R&D
development
clinical research
Action mechanism:
Disease: tuberculosis
Details: Aeras has signed an agreement with GSK Vaccins to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK\'s proprietary M72 antigen and AS01E* adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and one of the world\'s leading research-based pharmaceutical and healthcare companies marks advancement in the race to develop new vaccines against TB, a global infectious disease killer.
The new agreement comes after promising results from early stage clinical trials showed that the GSK TB vaccine candidate known as M72/AS01E* has an acceptable safety and reactogenicity profile and demonstrated an immune response. Under the new agreement, Aeras and GSK will each provide resources to run a multi-center proof of concept clinical trial to test the vaccine candidate in healthy adults between 18 and 50 years of age. The Phase IIb trial is scheduled to begin in Kenya, India and South Africa next year pending approvals from authorities.
Financial terms:
Latest news:
